Nuvamid
Launched in Lausanne in 2019, Nuvamid is a clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare diseases. Nuvamid’s Swiss team has developped a unique expertise with endogenous molecules to offer breakthrough therapeutics for the treatment of rare blood diseases. In cooperation with leading partners and institutions in Switzerland (Lausanne University), France (EFS, INSERM, CNRS), and the USA (Buck Institute), Nuvamid has aquired a unique knowledge in blood cells disorders. Our lead molecule NUV01, is currently evaluated in three Phase 2 trials. Nuvamid’s research is built upon the emerging scientific findings linking age-related disease pathologies with NAD metabolism. Nuvamid designed novel NAD metabolism modulators and gathered extensive preclinical data to develop a portfolio of drugs targeting immune disorders.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
3
11 to 50 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Nuvamid
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Nuvamid
2 distinct titles indexed · top 2 shown.
- 1chief medical officer
- 1r & d manager
Sign up to unlock all 2 contacts at Nuvamid
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Nuvamid
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.